Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946115 | 0.83 | NPC1 (0.49) | GRIN2BNPC1RAB9APOLB | |
| SCHEMBL7112664 | 0.72 | ALDH1A1 (0.57) | HTR2CNPC1RAB9AHTR2ALMNA | |
| SCHEMBL6957288 | 0.71 | MEN1 (0.52) | NPC1PKMRAB9ALMNA | |
| SCHEMBL5950094 | 0.71 | THRB (0.61) | GRIN2BHTR2CNPC1PKMRAB9A | |
| SCHEMBL15529643 | 0.71 | TRPV1 (0.60) | GRIN2BHTR2CNPC1PKMRAB9A | |
| SCHEMBL6947504 | 0.70 | CA2 (0.52) | — | |
| SCHEMBL17607255 | 0.70 | RAB9A (0.57) | CYP11B1CYP11B2HTR2CNPC1PKM | |
| SCHEMBL1960679 | 0.70 | TRPV1 (0.58) | GRIN2BHTR2CNPC1RAB9APOLB | |
| SCHEMBL32668648 | 0.69 | GRIN2B (0.55) | GRIN2BHTR2CLMNAPOLB | |
| SCHEMBL6304805 | 0.69 | HTR2C (0.70) | GRIN2BHTR2CNPC1RAB9AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027041-B1 | NOVEL CYANOAZIRIDINES FOR TREATING CANCER | AMPLIMED INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | VALLEY VENTURES III, L.P. | 2003-07-10 | — | — | US | disclosed |
| US-6297230-B1 | N-CARBAMOYL-SUBSTITUTED | AMPLIMED, INC. | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129222-A1 | Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer | ABHD16A, PNLIP, LIPA | GRIN2B 4678/4885AR 1206/4885CYP11B1 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.